{
"id":"mk19_a_np_q088",
"number":88,
"bookId":"np",
"correctAnswer":"D",
"title":"Question 88",
"stimulus":[
{
"type":"p",
"hlId":"a4c80b",
"children":[
"A 45-year-old man is evaluated during a routine follow-up visit for stage G3 chronic kidney disease. He also has hypertension and type 2 diabetes mellitus. Medications are cholecalciferol, hydrochlorothiazide, metformin, canagliflozin, and valsartan."
]
},
{
"type":"p",
"hlId":"d86653",
"children":[
"On physical examination, blood pressure is 140/80 mm Hg; other vital signs are normal. The remainder of the examination is normal."
]
},
{
"type":"p",
"hlId":"0f2071",
"children":[
"His calculated 10-year risk of an atherosclerotic cardiovascular disease event is 7.5%."
]
},
{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"lab-values table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"a462a3",
"children":[
"Laboratory studies:"
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"182194",
"class":"cell text l",
"children":[
"Total cholesterol"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"43dc3a",
"class":"cell text l",
"children":[
"186 mg/dL (4.8 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"8a43cb",
"class":"cell text l",
"children":[
"HDL cholesterol"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"82d326",
"class":"cell text l",
"children":[
"34 mg/dL (0.88 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"0c2f10",
"class":"cell text l",
"children":[
"LDL cholesterol"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"cc1f9b",
"class":"cell text l",
"children":[
"113 mg/dL (2.9 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"f461b2",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Creatinine, serum",
"children":[
"Creatinine"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"2bfd48",
"class":"cell text l",
"children":[
"2.0 mg/dL (176.8 µmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"77db81",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Glomerular filtration rate (GFR), urine",
"children":[
"Estimated glomerular filtration rate"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"33d604",
"class":"cell text l",
"children":[
"47 mL/min/1.73 m",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"2"
]
},
" "
]
}
]
}
]
}
]
}
]
}
],
"prompt":[
" ",
{
"type":"p",
"hlId":"d9913d",
"children":[
"Which of the following is the most appropriate treatment to reduce this patient's risk for atherosclerotic cardiovascular disease?"
]
},
" "
],
"options":[
{
"letter":"A",
"text":{
"__html":"Evolocumab"
}
},
{
"letter":"B",
"text":{
"__html":"Ezetimibe"
}
},
{
"letter":"C",
"text":{
"__html":"High-intensity rosuvastatin"
}
},
{
"letter":"D",
"text":{
"__html":"Moderate-intensity atorvastatin"
}
}
],
"keypoints":[
{
"type":"keypoint",
"hlId":"9cfd9b",
"children":[
"The use of statins to treat dyslipidemia in patients with chronic kidney disease has been shown to reduce cardiovascular events."
]
},
{
"type":"keypoint",
"hlId":"251ac6",
"children":[
"Statins do not slow progression of chronic kidney disease."
]
}
],
"exposition":[
{
"type":"p",
"hlId":"a10e0b",
"children":[
"The most appropriate treatment to reduce this patient's risk of atherosclerotic cardiovascular disease (ASCVD) is moderate-intensity atorvastatin (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option D"
]
},
"). The American College of Cardiology/American Heart Association Guideline on the Management of Blood Cholesterol recommends moderate-intensity statin therapy for any patient aged 40 to 75 years with diabetes mellitus. In addition, this guideline recognizes chronic kidney disease (CKD) as a risk enhancer for ASCVD and recommends a moderate-intensity statin for adults aged 40 to 75 years with an LDL cholesterol of 70 to 189 mg/dL (1.81-4.89 mmol/L) who have a 10-year ASCVD risk ≥7.5% (excluding patients treated with dialysis or kidney transplantation). The Kidney Disease: Improving Global Outcomes guidelines recommend treatment with a statin in all patients aged ≥50 years with non-dialysis–dependent CKD and in adults aged 18 to 49 years with non-dialysis–dependent CKD and any one of the following: coronary disease, diabetes, prior ischemic stroke, or a >10% estimated risk for coronary death or nonfatal myocardial infarction. The use of statins to treat dyslipidemia in patients with CKD has been shown to reduce cardiovascular events. However, statins do not slow progression of CKD. When patients reach end-stage kidney disease, statins do not reduce cardiovascular events. Atorvastatin is frequently chosen for patients with CKD because it undergoes hepatic clearance and does not require renal dose adjustments. In addition, atorvastatin may have beneficial effects on proteinuria."
]
},
{
"type":"p",
"hlId":"ceff67",
"children":[
"There is no indication for either evolocumab or ezetimibe (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Options A, B"
]
},
"). The proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, such as evolocumab, are monoclonal antibodies that bind to serine protease PCSK9, a liver enzyme that degrades hepatocyte LDL receptors. Adding a PCSK9 inhibitor can be considered for secondary prevention in very high-risk patients if the LDL cholesterol level remains ≥70 mg/dL (1.81 mmol/L) or the non-HDL cholesterol level is ≥100 mg/dL (2.59 mmol/L) despite maximally tolerated lipid-lowering therapy. Ezetimibe can be added to maximally tolerated statin therapy in very high-risk patients with clinically evident ASCVD when the LDL cholesterol level remains ≥70 mg/dL (1.81 mmol/L)."
]
},
{
"type":"p",
"hlId":"8997f6",
"children":[
"High-intensity statin therapy is not indicated in this patient, and atorvastatin is usually preferred to rosuvastatin (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option C"
]
},
"), a renally excreted statin, in patients with CKD."
]
}
],
"relatedSection":"mk19_a_np_s12_6_1_2",
"objective":{
"__html":"Prevent cardiovascular events in a patient with chronic kidney disease."
},
"references":[
[
"Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139:e1046-e1081. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/30565953",
"target":"_blank"
},
"children":[
"PMID: 30565953"
]
},
" doi:10.1161/CIR.0000000000000624"
]
],
"hospitalist":false,
"hvc":false,
"peerComparison":{
"A":0,
"B":2,
"C":40,
"D":58,
"E":0
},
"hlIds":[
"a4c80b",
"d86653",
"0f2071",
"a462a3",
"182194",
"43dc3a",
"8a43cb",
"82d326",
"0c2f10",
"cc1f9b",
"f461b2",
"2bfd48",
"77db81",
"33d604",
"d9913d",
"9cfd9b",
"251ac6",
"a10e0b",
"ceff67",
"8997f6"
]
}